Motilium Tropfen (Domperidone)

• Domperidone is employed to manage conditions linked to impaired gastrointestinal motility and nausea.
• Nausea and vomiting: reduces the frequency and severity of nausea and vomiting episodes.
• Gastroparesis: enhances gastric emptying and alleviates associated symptoms such as early satiety and bloating.
• Functional dyspepsia: improves upper abdominal discomfort, fullness and post‑prandial distress.

• Domperidone acts as a selective peripheral dopamine D2‑receptor antagonist. By blocking dopamine receptors in the chemoreceptor trigger zone and gastrointestinal smooth muscle, it diminishes nausea signals and stimulates gastric motility, thereby accelerating gastric emptying without significant central nervous system penetration.

Domperidone may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Dry mouth: reduced salivation leading to throat discomfort.
• Abdominal cramps: intermittent stomach pain.
• Headache: mild to moderate head pain.
• Dizziness: sensation of light‑headedness.
• Diarrhoea: loose stools.
• Constipation: reduced bowel movements.

Serious or Rare Side Effects

• Cardiac arrhythmia: irregular heart rhythm, especially with QT‑prolonging drugs.
• Extrapyramidal symptoms: involuntary muscle movements.
• Galactorrhoea: unexpected milk production.
• Severe allergic reactions: rash, swelling, or anaphylaxis.
• Hyperprolactinaemia: elevated prolactin levels causing hormonal effects.
• QT prolongation: potential for life‑threatening ventricular tachycardia.

• Before prescribing Domperidone, clinicians should consider several safety aspects.
• Assess cardiac risk: evaluate history of arrhythmia or prolonged QT interval.
• Monitor electrolytes: correct hypokalaemia or hypomagnesemia that may predispose to cardiac events.
• Use caution in hepatic impairment: dose adjustments may be required.
• Avoid in patients with prolactin‑dependent tumours: risk of tumour growth.
• Do not co‑administer with strong CYP3A4 inhibitors: may increase plasma concentrations.
• Store at room temperature: keep in the original container, protect from moisture and light.

Domperidone can interact with other medicines, altering its safety profile.

Major Interactions (Avoid)

• Quinidine: additive QT‑prolongation risk.
• Ketoconazole: strong CYP3A4 inhibition raises domperidone levels.
• Erythromycin: similar CYP3A4 inhibition effect.
• Other QT‑prolonging agents: combined risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely)

• Anticholinergics: may reduce gastrointestinal motility benefits.
• Other antiemetics: potential for overlapping side effects.
• Drugs metabolised by CYP3A4: monitor for altered plasma concentrations.